Editas Medicine, Inc. (EDIT) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Editas Medicine reported revenue of $40.5M, up 25.4% from $32.3M the year before. Net income was -$160.1M (a -395.0% net margin), or -$1.80 per diluted share. Operating margin was -394.9%. Operating activities generated -$165.2M of cash, leaving -$165.8M of free cash flow. At fiscal year end, Editas Medicine held $186.5M in total assets against $159.2M in total liabilities, including $146.6M of cash and equivalents.
Open the full interactive Editas Medicine financials → Quarterly statements, key ratios, valuation history and price charts.
Editas Medicine Key Stats
| Share Price | $2.44 |
|---|---|
| Market Cap | $291.7M |
| Revenue YoY Growth | +25.4% |
| 52-Week Range | $1.66 – $4.14 |
| Shares Outstanding | 119.3 million (basic, 2026 Q2) |
Editas Medicine Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Operating Income | -$134.8M | -$193.1M | -$225.9M | -$169.2M | -$251.2M | -$160.0M |
| Pre-Tax Income | -$116.0M | -$192.5M | -$220.4M | -$153.2M | -$237.1M | -$160.1M |
| Income Tax | — | — | $0 | $0 | $0 | $0 |
| Net Income | -$116.0M | -$192.5M | -$220.4M | -$153.2M | -$237.1M | -$160.1M |
| Diluted EPS | -$1.00 | -$2.83 | -$3.21 | -$2.02 | -$2.88 | -$1.80 |
Editas Medicine Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $7.5M | $24.7M | $2.8M | $11.9M |
| Net Income | -$25.1M | -$5.6M | -$25.0M | -$18.2M |
| Diluted EPS | -$0.28 | -$0.06 | -$0.26 | -$0.15 |
Editas Medicine Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $139.7M | $203.5M | $141.5M | $123.7M | $131.5M | $146.6M |
| Current Assets | $419.1M | $507.3M | $356.8M | $340.8M | $289.3M | $163.9M |
| Total Assets | $572.6M | $677.5M | $514.3M | $499.2M | $341.6M | $186.5M |
| Current Liabilities | $58.2M | $46.9M | $60.1M | $63.2M | $77.2M | $46.2M |
| Total Long-Term Debt | — | — | — | — | $57.4M | $58.6M |
| Total Liabilities | $179.0M | $123.8M | $153.6M | $150.1M | $207.3M | $159.2M |
| Shareholders' Equity | $393.6M | $553.6M | $360.7M | $349.1M | $134.3M | $27.3M |
Editas Medicine Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$179.8M | -$163.8M | -$177.3M | -$132.2M | -$210.3M | -$165.2M |
| Cash From Investing | -$140.5M | -$54.5M | $114.1M | -$3.7M | $162.1M | $138.7M |
| Cash From Financing | $224.1M | $282.1M | $1.3M | $118.0M | $56.0M | $40.5M |
| Free Cash Flow | -$187.0M | -$171.8M | -$181.5M | -$136.9M | -$219.1M | -$165.8M |
Figures from Editas Medicine's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Editas Medicine financials page for every line item.
Editas Medicine Company Profile
| Ticker | EDIT |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001650664 |
Frequently Asked Questions
What was Editas Medicine's revenue in fiscal 2025?
Editas Medicine (EDIT) reported revenue of $40.5M for fiscal 2025.
What is Editas Medicine's annual revenue history?
Editas Medicine's annual revenue by fiscal year: 2020: $90.7M; 2021: $25.5M; 2022: $19.7M; 2023: $78.1M; 2024: $32.3M; 2025: $40.5M.
What was Editas Medicine's net income in fiscal 2025?
Editas Medicine reported net income of -$160.1M for fiscal 2025.
What was Editas Medicine's earnings per share (EPS) in fiscal 2025?
Editas Medicine's diluted EPS was -$1.80 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Editas Medicine generate in fiscal 2025?
Editas Medicine generated -$165.8M of free cash flow in fiscal 2025.
What was Editas Medicine's revenue last quarter?
In its most recent reported quarter (2026 Q2), Editas Medicine reported revenue of $11.9M.
How much debt does Editas Medicine have?
Editas Medicine reported $58.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Editas Medicine are outstanding?
Editas Medicine reported a weighted average of 119.3 million basic shares outstanding in 2026 Q2.
What is Editas Medicine's market cap?
Based on its latest closing price, Editas Medicine (EDIT) has a market capitalization of about $291.7M.
When does Editas Medicine's fiscal year end?
Editas Medicine's fiscal year end, as registered with the SEC, is December 31.
Where is Editas Medicine headquartered?
Editas Medicine lists its business address in Cambridge, Massachusetts in its SEC filings.
Editas Medicine Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →